<DOC>
	<DOCNO>NCT01560923</DOCNO>
	<brief_summary>This randomize , double blind , multi-institutional phase II therapeutic study Indoximod placebo completion standard care sipuleucel-T ( Provenge® ) men asymptomatic minimally symptomatic metastatic prostate cancer castration resistant ( hormone refractory ) . Patients randomize receive either twice daily oral Indoximod placebo 6 month begin day third final sipuleucel-T infusion .</brief_summary>
	<brief_title>Phase II Study Sipuleucel-T Indoximod Patients With Refractory Metastatic Prostate Cancer</brief_title>
	<detailed_description>Sipuleucel-T administer standard care . Oral Indoximod/placebo self-administered twice daily 6 month start last infusion sipuleucel-T . Patients treat minimum 12 week Indoximod/placebo disease progression declare Indoximod/placebo discontinue increase prostate specific antigen ( PSA ) absence symptomatic clinical progression .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Tryptophan</mesh_term>
	<criteria>Histologically document adenocarcinoma prostate metastatic disease evidence soft tissue and/or bony metastasis baseline compute tomography ( CT ) scan abdomen pelvis and/or bone scan Castrationresistant base current historical evidence disease progression despite surgical medical castration demonstrate one following : PSA progression ( define two consecutive prostate specific antigen ( PSA ) measurement least 14 day apart ≥ 2.0 ng/ml ≥ 50 % minimum PSA castration therapy pretreatment value response ) progression measurable disease base Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion ( ≥ 50 % increase sum cross product measurable lesion development new lesion progression nonmeasureable disease Serum PSA ≥ 2.0 ng/ml study enrollment Castration level testosterone define ≤ 30 ng/dL study enrollment . Must least 3 month surgical castration must receive medical castration therapy least 3 month receive therapy time confirm disease progression Asymptomatic minimally symptomatic disease demonstrate Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 need opiate pain medication control pain/symptoms Age 18 year old Adequate bone marrow , renal hepatic function within 14 day study enrollment define : Bone marrow : WBC &gt; 3,000/uL ; absolute neutrophil count &gt; 1,500/uL ; platelet &gt; 100,000/uL Renal : creatinine within institutional upper limit normal ( ULN ) OR creatinine clearance &gt; 60 mL/min/1.73 m2 patient creatinine level ULN Hepatic : total bilirubin &lt; 1.5 X institutional ULN ; aspartate aminotransferase ( AST ( ( SGOT ) ) alanine aminotransferase ( ALT ( ( SGPT ) ) &lt; 2.5 X institutional ULN Chronic steroid dependence ( stop steroid supplementation 4 week prior enrollment ) Human immunodeficiency virus ( HIV ) positive patient acquired/inherited immunodeficiency History gastrointestinal disease cause malabsorption obstruction , limit Crohn 's disease , celiac sprue , tropical sprue , bacterial overgrowth/blind loop syndrome , gastric bypass surgery , stricture , adhesion , achalasia , bowel obstruction , extensive small bowel resection Inability take medication mouth History allergic reaction attribute compound similar chemical biologic composition Active autoimmune disease , chronic inflammatory condition , condition require concurrent use systemic immunosuppressant steroid . Mildintermittent asthma require occasional betaagonist inhaler use mild localized eczema exclude . Previous allotransplant kind History prior treatment antiCTLA4 blocking antibody</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>hormone refractory prostate cancer</keyword>
</DOC>